Form SC 14D9/A Care.com Inc Filed by: Care.com Inc
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 2)
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Name of Subject Company)
(Name of Person Filing Statement)
Common Stock, $0.001 par value per share (Common Stock)
Series A Convertible Preferred Stock, $0.001 par value per share (Preferred Stock)
(Title of Class of Securities)
141633107 (Common Stock)
None (Preferred Stock)
(CUSIP Number of Class of Securities)
General Counsel and Corporate Secretary
77 Fourth Avenue, Fifth Floor
Waltham, MA 02451
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on
Behalf of the Person Filing Statement)
With copies to:
John H. Chory
Bradley C. Faris
Susan L. Mazur
Latham & Watkins LLP
200 Clarendon Street, 27th Floor
Boston, MA 02116
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This Amendment No. 2 (this Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, this Schedule 14D-9) filed by Care.com, Inc. with the Securities and Exchange Commission on January 13, 2020, relating to the tender offer (the Offer) by Buzz Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of IAC/InterActiveCorp, a Delaware corporation, to purchase (i) all of the outstanding Common Shares at a purchase price of $15.00 per Common Share and (ii) all of the outstanding Preferred Shares at (x) 150% of the Liquidation Preference per share, as specified in the Certificate of Designations for the Preferred Shares (the Certificate of Designations), plus (y) Accrued and Unpaid Dividends payable in respect of such Preferred Shares, as specified in the Certificate of Designations, in the case of clauses (x) and (y), calculated as of and including the expiration date for the Offer, pursuant to the terms of the Certificate of Designations, in each case, net to the holder in cash, without interest, less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 13, 2020, and in the related Letter of Transmittal, each of which may be amended or supplemented from time to time.
Except to the extent specifically provided in this Amendment, the information set forth in this Schedule 14D-9 remains unchanged. Capitalized terms used, but not otherwise defined, in this Amendment shall have the meanings ascribed to them in this Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below.
Item 8. Additional Information.
Item 8 of this Schedule 14D-9 is hereby amended and supplemented by replacing the sentence under the heading Legal Proceedings on page 53 with the following:
On January 21, 2020, a purported stockholder class action complaint, captioned Kent v. Care.com, Inc., et al., Case No. 1:20-cv-00088, was filed in the United States District Court for the District of Delaware. The complaint names as defendants Care.com, the individual members of the Care.com Board, IAC and Merger Sub. The complaint alleges, among other things, that all defendants violated provisions of the Exchange Act insofar as the Schedule 14D-9 filed by Care.com on January 13, 2020 allegedly omits material information with respect to the transactions contemplated by the Merger Agreement, including the Offer and the Merger, that purportedly renders the Schedule 14D-9 false and misleading. The complaint seeks, among other things, injunctive relief, rescissory damages, declaratory judgment and an award of plaintiffs fees and expenses. The defendants believe the claims asserted in the complaint are without merit.
Item 8 of this Schedule 14D-9 is hereby amended and supplemented by adding the following sentences as a new paragraph at the end of the subsection titled Antitrust ComplianceGermany on page 53:
The required Phase I review period under the German Competition Act with respect to the Offer and the Merger was terminated on January 24, 2020, and no Phase II investigation was opened. Accordingly, the condition of the Offer relating to obtaining approval under the German Competition Act has been satisfied. The Offer continues to be subject to the remaining conditions set forth in Section 13Conditions of the Offer of the Offer to Purchase.